Rinat Neuroscience Corp.
This article was originally published in Start Up
Executive Summary
None of the marketed humanized monoclonal antibodies and very few of those in development target nervous system disorders. Rinat Neuroscience Corp. hopes to turn heads by pioneering highly targeted antibody therapies for pain, neuropathy and other neural disorders.
You may also be interested in...
Therapeutic Antibody Start-Ups
After more than a decade of anticipation, pharmas have now clearly recognized the value of antibodies as therapeutics. And biotechs can offer discovery tools and development expertise.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.